Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

HepCgen genotyping service helps fight Hepatitis C, a "silent epidemic"

22.07.2003


Genotyping provides route to tailored treatment at lower cost with less side effects

A new centralised genotyping service that enables clinicians to differentiate between types of hepatitis C infections is poised to improve treatment for patients with Hepatitis C, a severely under treated viral infection in the UK. The new service, available through HepCgen will allow clinicians to tailor costly interferon-based treatment regimes to the patients’ viral genotype, thus lowering costs and side effects.

Although five times more prevalent than HIV, most cases of Hepatitis C go undetected, prompting the phrase ‘the silent epidemic’, therefore it is important that, once identified, diagnosis and treatment commence without delay. “HepCgen’s centralised Hepatitis C genotyping service allows hospitals throughout the UK extremely rapid access to this important information, without the need for an expensive and time consuming in-house genotyping set up”, said Paul Colford, CEO of HepCgen.



Through early identification of patients with genotype 1, or non-1, HepCgen is able to distinguish patients that may require lower doses for shorter periods of time. This knowledge not only has obvious benefits to the patient by reducing medication and associated side effects, but also provides a significant cost saving to healthcare funders: HepCgen founder Dr William Rosenberg estimates a saving to the NHS of half a billion pounds a year if doctors routinely use this service.

HepCgen regards cost of treatment as a significant factor in the number of patients undergoing treatment for Hepatitis C and Dr Rosenberg notes, “Of the 400,000 cases in the UK only about 20,000-30,000 are in secondary care and of those, only some 2,000 cases are being treated, because the NHS won’t release funding for treatment.”

Further evidence of the importance placed on genotyping in the treatment of hepatitis C came with Roche’s announcement on 18th July of the European Commission’s approval of a new label for PEGASYS, Roche’s flagship treatment for the hepatitis C virus. The approval came as a result of a pivotal study by Roche, demonstrating that the duration of combination therapy and dose of Copegus (ribavirin) for chronic hepatitis C patients depends on viral genotype. Dr. Rosenberg continues, “We have demonstrated similar data with the Schering-Plough therapy, among others. The importance of identifying genotype in the treatment of Hepatitis C is becoming rapidly accepted. This recognition by the European Commission is strong additional testimony.”

“HepCgen currently provides its proprietary services to over 20 centres in the UK, most of which are reimbursed by the major pharmaceutical companies involved in Hepatitis C”, stated Mr Colford. “We would like to expand our services throughout Europe, as countries like Italy, Germany, and France are treating over five times the number of patients the UK chooses to, and will tremendously benefit by either using HepCgen services or licensing this technology. ”

HepCgen Ltd was recently spun out of the University of Southampton and specialises in diagnostics and treatments for chronic liver disease. Dr. Spike Willcocks, IP2IPO adds, “HepCgen is a very exciting opportunity in our portfolio, whose technology meets a now widely recognised medical need, and this step demonstrates the increasing value of the Company. Further development in this area could be rapidly accelerated with additional financing in the near future.”

For more information, please contact:

At the company

Paul Colford, CEO HepCgen Ltd, paul.colford@hepcgen.com
Dr William Rosenberg, wmr@soton.ac.uk

Media enquiries

Dr. Spike Willcocks, IP2IPO, spike.wilcocks@ip2ipo.com
Sue Charles, Northbank Communications, s.charles@northbankcommunications.com
James Parkinson, Northbank Communications, j.parkinson@northbankcommunications.com

Louise Johnson | alfa
Further information:
http://www.hepcgen.com

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>